A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition

Yong Fang, Yihong Wang1, Yulei Wang2

  • 1‡Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.

The Biochemical Journal
|August 15, 2014
PubMed

Insights

Reduced p27Kip1 expression is linked to increased EGFR, promoting cancer. This study reveals p27Kip1 suppresses tumor growth by inhibiting the JNK/c-Jun pathway and EGFR expression, offering new therapeutic insights.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Cycle Regulation

Background:

  • p27Kip1 (cyclin-dependent kinase inhibitor) is crucial for cell cycle control.
  • Decreased p27Kip1 is common in human tumors, but its tumor suppressive mechanisms are not fully understood.
  • Epidermal Growth Factor Receptor (EGFR) is frequently overexpressed in cancers.

Purpose of the Study:

  • To elucidate the mechanism of p27Kip1-mediated tumor suppression.
  • To investigate the relationship between p27Kip1 and EGFR expression in cancer.
  • To identify the signaling pathway involved in p27Kip1 regulation of EGFR.

Main Methods:

  • Comparative analysis of p27Kip1 and EGFR expression in human bladder cancer cell lines (T24 and T24T) and tissues.
  • Gene depletion studies in mouse embryonic fibroblast (MEF) cells.
  • Promoter-luciferase reporter assays to assess transcriptional regulation.
  • Western blotting and dominant-negative mutant studies to analyze signaling pathways (JNK/c-Jun).
  • Functional assays including anchorage-independent growth.

Main Results:

  • An inverse correlation was observed between p27Kip1 and EGFR expression in cancer cells and tissues.
  • p27Kip1 deficiency led to increased EGFR expression, suggesting transcriptional repression.
  • p27Kip1 suppresses EGFR transcription via the JNK/c-Jun signaling pathway.
  • Restoration of p27Kip1 inhibited JNK/c-Jun activation, EGFR expression, and cancer cell growth.

Conclusions:

  • p27Kip1 acts as a tumor suppressor by inhibiting the JNK/c-Jun pathway, thereby repressing EGFR expression.
  • This mechanism contributes to the suppression of cancer cell growth, migration, and metastasis.
  • Findings provide novel insights into p27Kip1's role in cancer and potential therapeutic strategies targeting the p27Kip1-EGFR axis.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K